Answers are grounded in this paper and cite their sources.
To quantify the magnitude of an ISPOR novel value element, insurance value, as applied to new treatments for a rare, severe disease with pediatric onset: Duchenne muscular dystrophy (DMD).
No takes yet. Share an insight, caveat, or question.
Shafrin et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: